Clinical Trials · NCT03839823

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Name: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 222
Start date: Feb 2019
Locations: 50 sites, 13 countries
Primary endpoint: Progression-free Survival

View Gonadorelin compound reference